HC Wainwright Boosts Earnings Estimates for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – Investment analysts at HC Wainwright increased their Q4 2026 earnings per share (EPS) estimates for shares of Rockwell Medical in a note issued to investors on Monday, January 26th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.01 per share for the quarter, up from their prior forecast of ($0.01). HC Wainwright has a “Buy” rating and a $2.50 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share.

A number of other research analysts have also commented on RMTI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rockwell Medical in a research note on Thursday, January 22nd. Wall Street Zen cut Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $2.50.

Rockwell Medical Stock Up 5.5%

RMTI stock opened at $1.15 on Tuesday. The firm’s 50-day moving average is $0.94 and its two-hundred day moving average is $1.11. The company has a market capitalization of $45.31 million, a price-to-earnings ratio of -7.19 and a beta of 1.65. Rockwell Medical has a 52 week low of $0.78 and a 52 week high of $2.15. The company has a current ratio of 3.91, a quick ratio of 3.50 and a debt-to-equity ratio of 0.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after acquiring an additional 148,737 shares during the period. GSA Capital Partners LLP grew its position in shares of Rockwell Medical by 635.1% in the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after purchasing an additional 141,672 shares during the last quarter. Finally, Panagora Asset Management Inc. bought a new position in shares of Rockwell Medical in the second quarter worth about $41,000. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.